Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Parkinson's drug ABBV-951 under Real-World watch in japan

NCT ID NCT05916157

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 250 adults with advanced Parkinson's disease who are prescribed ABBV-951 by their doctors. The goal is to see how safe and effective the drug is in everyday use over 52 weeks. Participants continue their normal care with no extra visits required.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants who are prescribed ABBV-951 for the treatment of advanced Parkinson's disease (aPD).

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with advanced Parkinson's disease (aPD). * Prescribed ABBV-951 as physicians' decision according to the approved label for treatment of aPD. * Given informed consent (or by her/his legal representative, if it's a requirement from the participating hospital/clinic) for participating this study. Exclusion Criteria: * Prior treatment with ABBV-951 for PD. * Currently participating in interventional clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease (PD)

Contacts and locations

Locations

  • Dokkyo Medical University Hospital /ID# 269116

    Mibu, Tochigi, 321-0293, Japan

  • Fujimoto General Hospital /ID# 277287

    Miyakonojo-shi, Miyazaki, 885-0055, Japan

  • Hakodate Municipal Hospital /ID# 276757

    Hakodate-shi, Hokkaido, 041-8680, Japan

  • Juntendo University Hospital /ID# 264438

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Municipal Toyonaka Hospital /ID# 271277

    Toyonaka, 560-0055, Japan

  • National Center of Neurology and Psychiatry - Kodaira /ID# 267372

    Xiaoping City, Tokyo, 187-8551, Japan

  • National Hospital Organization Asahikawa Medical Center /ID# 269115

    Asahikawa, Hokkaido, 070-0901, Japan

  • National Hospital Organization Utano Hospital /ID# 268350

    Kyoto, 616-8255, Japan

  • Nitobe Memorial Nakano General Hospital /ID# 275668

    Nakano-ku, Tokyo, 164-0011, Japan

  • Okatsu Hospital /ID# 262781

    Kagoshima, Kagoshima-ken, 890-0067, Japan

  • Okayama Neurology Clinic /ID# 269117

    Okayama, 702-8005, Japan

  • Ryugasaki Saiseikai Hospital /ID# 264435

    Ryūgasaki, Ibaraki, 305-0854, Japan

  • Saiseikai Matsuyama Hospital /ID# 276259

    Matsuyama, Ehime, 791-8026, Japan

  • Sendai Nishitaga National Hospital /ID# 268349

    Sendai, Miyagi, 982-8555, Japan

  • Shiga University of Medical Science Hospital /ID# 265637

    Ōtsu, Shiga, 520-2192, Japan

  • University Hospital Kyoto Prefectural University of Medicine /ID# 267445

    Kyoto, Kyoto, 602-8566, Japan

  • University of Tsukuba Hospital /ID# 268353

    Tsukuba, Ibaraki, 305-8576, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.